[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"superficial-vein-thrombosis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:superficial-vein-thrombosis":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,44,70],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":27,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100644557","superficial-vein-thrombosis-testing-in-the-emergency-department-100644557",false,"NCT07671300","Superficial Vein Thrombosis Testing in the Emergency Department","Evaluating Superficial Vein Thrombosis in the Emergency Department.","SVTest","Inclusion Criteria:\n\n* Aged ≥ 18\n* Tested for superficial vein thrombosis in the emergency department or urgent care centre\n* Patients tested for SVT at all sites, including arms, legs and torso\n\nExclusion Criteria:\n\n* Patient opted out of research at the participating site\n* Patient included in the study in the last 90 days","ALL","18 Years",{"count":20,"type":21},400,"ESTIMATED","OBSERVATIONAL","Superficial vein thrombosis (SVT) occurs when blood in a vein directly under the skin clots. SVT causes vein tenderness, pain, and skin discolouration. Over time, the vein hardens into a firm, nontender, easily palpable lump. SVT commonly occurs in the veins of the leg. Each year, 1 per 1000 people over the age of 18 have a superficial vein thrombosis (SVT). SVT is painful but usually gets better within a month. Four in 100 people with SVT develop progressively worse blood clotting involving the deep veins or lungs.\n\nIf a deep vein clot in the leg occurs it can cause permanent disability with post-thrombotic syndrome (long-term leg pain and swelling) and reduced quality of life. If a pulmonary embolism occurs it may causes chest pain, breathlessness, pulmonary hypertension, psychological distress, and potentially death.\n\nRisk factors for SVT include varicose veins, pregnancy, cancer, the use of intravenous catheters, a history of venous thromboembolism, age, and thrombophilia.\n\nGuidelines tell doctors to use ultrasound scanning to decide whether SVT needs treatment with a blood thinner or not. Blood thinners prevent the clot from worsening.\n\nMany people who have SVT go to the emergency department. Scanning is limited to the daytime so often people have multiple trips to the emergency department for their scan and they spend many hours waiting for a doctor to see them.\n\nOur research group developed simple ways to limit the need for scans for other types of blood clots, like blood clots in the lungs or in the deep veins. We use a simple blood test called D-dimer. We believe we may be able to use D-dimer to help limit the need for SVT scanning.\n\nThis is an exploratory study to document what happens to patients tested for SVT in the emergency department, and to see if the D-dimer blood test might be useful in reducing scans. We will review the emergency department charts for patients who came to the emergency department with SVT. Our results will tell us whether further studies would be helpful.",[25,26],"Superficial Vein Thrombosis","D-dimer",[26,28,29,30],"Superficial vein thrombosis","Emergency Medicine","diagnostic","NOT_YET_RECRUITING","2026-06-22",{"date":34,"type":35},"2026-06-26","ACTUAL",{"date":37,"type":21},"2026-07-15",{"date":39,"type":21},"2029-07",{"name":41,"class":42},"Dr. Kerstin de Wit","OTHER",1,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":48,"acronym":49,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":51,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":53,"conditions":54,"keywords":57,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":43},"100609139","prospective-evaluation-of-the-treatment-of-cancer-associated-superficial-venous-100609139","NCT07210671","Prospective Evaluation of the Treatment of Cancer Associated Superficial Venous","SUPERCAT","Inclusion Criteria:\n\n* Patient over 18\n* Patient affiliated to a social security scheme\n* Patient who understands French\n* Patient with superficial venous thrombosis of the lower and upper limbs confirmed by a Doppler ultrasound less than one month old.\n* Patient with active cancer:\n* Cancer treatment within the last 6 months,\n* Detectable tumor disease, cancer treatment within the last 6 months, ongoing hormone therapy for cancer, palliative cancer.\n* The patient has received potentially non-curative cancer treatment (notably palliative chemotherapy).\n* Progression shows that the cancer treatment was not curative (due to recurrence or progression under treatment) (particularly in the case of recurrence after surgery)\n\nExclusion Criteria:\n\n* Patients under legal protection\n* Patients with concomitant pulmonary embolism\n* Patient with proximal or distal deep vein thrombosis\n* Patient treated with anticoagulant therapy for another indication\n* Patient with a contraindication to anticoagulation: Thrombocytopenia less than 30,000 elements\u002Fmm3, active bleeding or history of severe bleeding.\n* Patient opposed to participation in research",{"count":52,"type":21},1576,"Superficial venous thrombosis (SVT) is very common in clinical practice. What's more, around 15- 20% of SVTs occur in the context of cancer. Today, cancer patients are excluded from therapeutic trials for DVT. There is therefore no high-level evidence-based treatment recommendation for these patients. Recent data suggest that the course of cancer-associated DVT is similar to that of cancer-associated deep vein thrombosis (DVT). However, there are currently few prospective data on the evolution of cancer-associated DVT in relation to the treatment used. Due to the absence of clear recommendations of treatment in case of SVT associated with cancer the investigators will perform a prospective observational study to evaluate the efficacy of different regiment of anticoagulant treatment ordered in clinical practice.",[25,55,56],"Cancer","Venous Thrombosis",[28,58,59],"cancer","venous thrombosis","RECRUITING","2026-04-09",{"date":63,"type":35},"2026-04-14",{"date":65,"type":35},"2025-11-10",{"date":67,"type":21},"2028-11",{"name":69,"class":42},"Centre Hospitalier Universitaire, Amiens",{"id":71,"slug":72,"hasResults":11,"nctId":73,"briefTitle":74,"officialTitle":75,"acronym":76,"eligibilityCriteria":77,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":78,"targetDuration":4,"studyType":80,"phases":81,"briefSummary":84,"conditions":85,"keywords":88,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":103},"100590329","phase-2-a-pilot-trial-comparing-full-dose-rivaroxaban-to-prophylactic-dose-rivaroxaban-in-patients-with-superficial-vein-thrombosis-in-the-leg-100590329","NCT06965998","A Pilot Trial Comparing Full Dose Rivaroxaban to Prophylactic Dose Rivaroxaban in Patients With Superficial Vein Thrombosis in the Leg","A Pilot Randomized Double-Blinded Comparison of Full Treatment Dose Rivaroxaban for 90 Days to Prophylactic Dose Rivaroxaban for 45 Days in Patients With Lower Extremity Superficial Vein Thrombosis","RIVA-SVT","Inclusion Criteria:\n\n1. Adult patients age ≥ 18 years old.\n2. Objectively confirmed diagnosis within 14 days of an acute symptomatic SVT of the lower extremities by standardized CUS, where SVT is defined as incompressibility of a venous segment located along the course of a known superficial vein.\n3. Anticoagulation for SVT is warranted per clinicians.\n4. Able and willing to provide written informed consent.\n\nExclusion Criteria:\n\n1. Other indication(s) for therapeutic or prophylactic dose anticoagulation (e.g. atrial fibrillation, mechanical valve, etc.).\n2. History of PE or DVT within 6 months (180 days) of screening.\n3. \\>5 days of any anticoagulants for the index SVT.\n4. Requires use of aspirin \\>100mg daily or other antiplatelet agents.\n5. Patients receiving concomitant systemic treatment with strong inhibitors of both CYP 3A4 and P-gp (e.g. cobicistat, ketoconazole, itraconazole, posaconazole, ritanovir, etc.).\n6. Active bleeding or history of CRNMB or major bleeding (as defined by the ISTH) within 30 days of screening.\n7. History of severe head trauma or ophthalmic, spinal, cerebral surgery within 90 days of screening.\n8. Have acute endocarditis.\n9. Thrombocytopenia (platelet count \\\u003C50,000\u002FuL), acute hepatitis, chronic active hepatitis, cirrhosis with severe hepatic impairment defined by a Childs-Pugh class B or C.\n10. Creatinine clearance \\\u003C30 ml\u002Fmin.\n11. Known contraindication to treatment with rivaroxaban.\n12. Are participating in another interventional trial that would compromise the results or integrity of this trial as determined by the investigator.\n13. Pregnant or breast feeding.\n14. Known hereditary or acquired severe hemorrhagic disease.\n15. Life expectancy \\\u003C3 months.\n16. Unstable medical or psychological condition that would interfere with trial participation at the discretion of the site investigator.",{"count":79,"type":21},50,"INTERVENTIONAL",[82,83],"PHASE2","PHASE3","The goal of this clinical trial, called a pilot study or a feasibility study, is to test the study plan and to find out whether enough participants will join a larger study and accept the study procedures. This type of study includes a small number of participants so it is not expected to prove how safe the treatment is or how well the treatment works.\n\nThe main question it hopes to answer is:\n\n1.What is the average number of patients that are recruited per month during the 12 month study period?\n\nTo test the study plan, adults being treated for a superficial vein thrombosis (SVT), which is a blood clot in the superficial veins of the leg, will be given a type of blood thinner called rivaroxaban. Half of the participants in this study will be given the standard (low-dose) rivaroxaban for 45 days, then 45 days of placebo (a substance that looks like the study medication but does not have any active or medicinal ingredients). The other half of participants will be given full-dose rivaroxaban for a total of 90 days. The placebo in this study is not intended to have any effect on the participants blood clot. A placebo is used to make the results of the study more reliable.",[86,87,25],"SVT","Thrombosis",[89,90,91,92,93,28],"Pilot","Rivaroxaban","Feasibility","Full dose rivaroxaban","Treatment dose rivaroxaban","2025-08-05",{"date":96,"type":35},"2025-08-11",{"date":98,"type":35},"2025-08-06",{"date":100,"type":21},"2027-02",{"name":102,"class":42},"Ottawa Hospital Research Institute",2]